Alzheimer’s disease(AD) is a progressive and age-related irreversible neurodegenerative disease. When AD occurs, the relevant amount of zinc ions in brain considerably changes. In this contribution, we have explored the possibility of in vivo rapid fluorescence imaging of AD through accurate targeting biomarker of zinc gluconate. By using the 3- and 6-month-old Alzheimer’s model mice(AD-1) as the experimental models, our observations demonstrate that zinc gluconate molecules could pass through the blood–brain barrier and then produce hippocampus region-specific accumulation of fluorescent zinc nanoclusters in vivo, thus allowing kinetically controlled selective imaging of AD by fluorescence bioimaging.
Alzheimer's disease (AD) is a progressive and age-related irreversible neurodegenerative disease. When AD occurs, the relevant amount of zinc ions in brain considerably changes. In this contribution, we have explored the possibility of in vivo rapid fluorescence imaging of AD through accurate targeting biomarker of zinc gluconate. By using the 3- and 6-month-old Alzhei- mer's model mice (AD-1) as the experimental models, our observations demonstrate that zinc gluconate molecules could pass through the blood-brain barrier and then pro- duce hippocampus region-specific accumulation of fluo- rescent zinc nanoclusters in vivo, thus allowing kinetically controlled selective imaging of AD by fluorescence bio- imaging.